Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abstract: A novel crystal form of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Abstract: A treatment agent for elastic polyurethane fibers comprising a dispersion in which a higher fatty acid magnesium salt is colloidally dispersed in a silicone mixture consisting of a silicone oil with a viscosity of 5×10−6−50×10−6 m2/S at 25° C. as a dispersion medium and a dispersant mainly comprising a modified silicone at a ratio by weight of the dispersion medium/the dispersant=100/0.5-100/4.5, wherein the amount of the higher fatty acid magnesium salt is 1 to 10 parts by weight per 100 parts by weight of the silicone oil.

Abstract: A treatment agent for elastic polyurethane fibers comprising a dispersion in which a higher fatty acid magnesium salt is colloidally dispersed in a silicone mixture consisting of a silicone oil with a viscosity of 5×10−6−50×10−6 m2/S at 25° C. as a dispersion medium and a dispersant mainly comprising a modified silicone at a ratio by weight of the dispersion medium/the dispersant=100/0.5−100/4.5, wherein the amount of the higher fatty acid magnesium salt is 1 to 10 parts by weight per 100 parts by weight of the silicone oil.

Abstract: An imidazopyridine derivative of the formula ?I!: ##STR1## wherein R.sup.1 is a lower alkyl group, R.sup.2 is a lower alkanoyl group, and R.sup.3 and R.sup.4 are each lower alkyl groups, or both combine at the end thereof to form an alkylene group having 3 to 6 carbon atoms, and a pharmaceutically acceptable salt thereof, said imidazopyridine derivatives have an excellent angiotensin II antagonistic activity and are useful for the prophylaxis or treatment of hypertension.